Barclays
SLDB icon

Barclays’s Solid Biosciences SLDB Stock Holding History

Barclays’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-667
Closed -$45K – 6429
2019
Q4 		$45K Sell
667
-7,760
-92% -$856K ﹤0.01% 5765
2019
Q3 		$1.31M Sell
8,427
-5,666
-40% -$641K ﹤0.01% 3390
2019
Q2 		$1.22M Buy
+14,093
New +$1.54M ﹤0.01% 3482

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Barclays's SLDB Position: Q1 2026 in Review

Barclays reduced its Solid Biosciences (SLDB) stake by 57% in Q1 2026, selling an estimated $509K and leaving 58,877 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #3283.

Barclays first reported a position in SLDB in Q1 2018 and has held it in 33 quarters since. The position peaked at $3.94M in Q1 2019. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Barclays held 58,877 shares of Solid Biosciences worth $424K as of Q1 2026.
  • Barclays sold 79,259 Solid Biosciences shares in Q1 2026, an estimated $509K.
  • Solid Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3283 holding.
  • Barclays first reported a position in Solid Biosciences in Q1 2018 and has held it in 33 quarters since.
  • Barclays's Solid Biosciences position peaked at $3.94M in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.